Humacyte (HUMA) Non Operating Investment Income (2020 - 2021)

Humacyte (HUMA) reported Non Operating Investment Income of $12.0 for Q2 2021, down 36.84% quarter-over-quarter from $19.0 in Q1 2021.

Humacyte (HUMA) Non Operating Investment Income (2020 - 2021) Analysis & Trends

Humacyte (HUMA) has 2 years of Non Operating Investment Income data on file, last reported at $12.0 in Q2 2021.

Non Operating Investment Income for Q2 2021 came in at $12.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2021 was -$5955.0 (changed N/A YoY), and the FY2020 annual result was $16191.0, changed N/A from the prior year.
Non Operating Investment Income eased to $12.0 in Q2 2021 per HUMA's latest filing, from $19.0 in the prior quarter.
Over five years, Non Operating Investment Income peaked at $16191.0 in Q4 2020 and troughed at -$22177.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Investment Income (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	235,807.00
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	230,000.00
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Humacyte	183.21 Mn	134.67 Mn	-1.54 Mn	-

Download Data